MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

What Happened with aTyr Pharma's Initial Phase 3 Trial

1 day ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Happened with Olaplex's Q4 2025 Earnings

2 months ago

What Just Happened with BD and Waters

2 months ago

What's Behind the Recent Insider Selling at NewAmsterdam Pharma (NAMS)

2 months ago

Did MasTec's Q4 2025 Earnings Signal a New Growth Phase

2 months ago

aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial

aTyr Pharma will initiate a new Phase III trial for efzofitimod in pulmonary sarcoidosis following recent feedback from the FDA. This strategic pivot follows a Type C meeting with regulators to align ...

ATYR

Stock News•5 days ago

Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why

Entrada Therapeutics (TRDA) shares fell sharply Thursday following the release of clinical trial data for its Duchenne muscular dystrophy treatment. The market reaction reflects investor concerns rega...

TRDA

Stock News•5 days ago

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock reported Q1 2026 financial results and business updates, highlighting progress in its myostatin biology platform for spinal muscular atrophy. The company continues to advance its clinical...

SRRK

Stock News•1 week ago

Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atrophy Transcript

Alterity Therapeutics (ATHE) outlined its Phase II development strategy for ATH434, a candidate targeting Multiple System Atrophy. The company discussed clinical data and future regulatory pathways, a...

ATHE